Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2026 · $116.3MThe company’s own SEC segment disclosure.
- United States$70.2M60%
- Non Us$46.1M40%
Insmed Incorporated (INSM) reported revenue of $425M in Q2 2026 (quarter ended Jun 30, 2026), up 296% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $13M. For the full year FY2025, revenue was $606M (+67% year on year) and net income −$1.28B. Its largest region in Q2 2026 was United States at $70M, 60% of the disclosed total, well ahead of Non Us at 40%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #91 of 143 by Smart Score